Released May 14, 2021, after the close
10-Q filed May 14, 2021, 44 days after period end · 0001564590-21-027997
Q1 2021 · 10-Q
Revenue$1.66M$1.66M −29.7% vs Q1 2020+12.4% vs Q4 2020
Net Income-$599.00K-$599.00K N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.08-$0.08 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$567,000N/M
Operating Cash Flow-$394,000N/M
Margins · derived
Operating margin-34.2%−14.9 pt vs Q1 2020
Net margin-36.1%−20.3 pt vs Q1 2020
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $1.66M | $2.36M | $2.22M | $2.63M |
| Net Income | -$599.00K | -$373.00K | -$906.00K | -$830.00K |
| EPS Diluted | -$0.08 | -$0.05 | -$0.12 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
International Stem Cell CORP · CIK 1355790 · Engraved from SEC EDGAR